Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Rationale: Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH)
has historically had a poor prognosis, with a 1-year survival rate among patients …

Rationale: Incident pulmonary arterial hypertension was underrepresented in most pulmonary
hypertension registries and may have a different disease profile to prevalent disease. …

Rationale: The management of chronic thromboembolic pulmonary hypertension (CTEPH)
has changed over recent years with the growth of pulmonary endarterectomy surgery and the …

Guidelines summarize and evaluate available evidence, with the aim of assisting health
professionals in proposing the best management strategies for an individual patient with a given …

Background— Chronic thromboembolic pulmonary hypertension results from incomplete
resolution of pulmonary emboli. Pulmonary endarterectomy (PEA) is potentially curative, but …

Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the …

After the approval of bosentan for the treatment of pulmonary arterial hypertension (PAH),
European authorities required the introduction of a post-marketing surveillance system (PMS) …

Background Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary
arterial hypertension (PAH) as parenteral or inhaled therapy. Treprostinil diolamine, a …